Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing next-generation immunotherapies using its proprietary ImmunoPhage™ phage-based platform. The platform uses genetically engineered bacteriophage to generate robust immune responses to tumor antigens and block immunosuppressive pathways, and is designed for rapid, inexpensive, and scalable manufacturing. Sensei is expanding its pre-manufactured, GMP-grade Phortress™ library to enable a personalized yet off‑the‑shelf cocktail approach that can be customized for patients quickly. Its lead candidate, SNS-301, is in a Phase 1/2 trial in combination with pembrolizumab for advanced SCCHN, with promising interim results reported and topline readout expected by the end of 2021. The company is also advancing preclinical programs SNS-401 (Merkel cell carcinoma ImmunoPhage cocktail) and SNS‑VISTA (anti‑VISTA antibody). Sensei is using newly raised capital to advance its clinical pipeline and broaden development of its ImmunoPhage platform.

Total raised

$30M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2021